Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Yocom

Neurological Surgery Camden, NJ Doctor of Osteopathy

NPI 1730272550 CMS profile 726203

3 Cooper Plz, Suite 104, Camden, NJ 08103

Open in the dashboard

General payments

$152,556

67 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Yocom of Camden, NJ is reported in the CMS Open Payments database as having received $152,556 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,556 14
2024 General $25,455 12
2023 General $16,014 7
2022 General $20,812 10
2021 General $28,133 7
2020 General $15,067 4
2019 General $24,518 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Yocom
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Steven Yocom were reported at $22,556. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Steven Yocom Neurological Surgery median Middle half National median
2019 $24,518 $582 $138–$3,006 $163
2020 $15,067 $294 $76–$2,174 $114
2021 $28,133 $387 $105–$2,432 $132
2022 $20,812 $542 $139–$2,989 $149
2023 $16,014 $534 $145–$2,697 $160
2024 $25,455 $574 $155–$3,046 $164
2025 $22,556 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Precision Spine, Inc. $148,744 49 payments
  2. Brainlab, Inc. $3,271 7 payments
  3. Dilon Technologies, Inc. $137 1 payment
  4. ulrich medical USA, Inc. $122 1 payment
  5. Medtronic, Inc. $118 2 payments
  6. Globus Medical, Inc. $92 3 payments
  7. Zimvie Inc. $23 1 payment
  8. Stryker Corporation $22 1 payment
  9. CONMED Corporation $15 1 payment
  10. KARL STORZ Endoscopy-America $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $109,977 24 payments
  2. Consulting Fee $38,111 17 payments
  3. Travel and Lodging $3,190 6 payments
  4. Food and Beverage $1,278 20 payments
Products named General payments · program years 2019–2025
  1. SURE-LOK EXTENDED TAB PEDICLE SCREW SYSTEM $72,928 18 payments
  2. REFORM POCT SYSTEM Orthopedics $62,067 17 payments
  3. SLC Extended Tab Orthopedics $36,128 7 payments
  4. Reform Poct $25,032 5 payments
  5. SLC Extended Tab Orthopedics $25,032 5 payments
  6. REFORM POCT SYSTEM Orthopedics $13,860 3 payments
  7. Dakota ACDF System $8,288 8 payments
  8. Reform POCT Occipital System $3,000 1 payment
  9. Reform Ti Pedicle Screw System $2,000 2 payments
  10. Reform Pedicle Screw System $2,000 1 payment
  11. Other $1,786 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

232

Median for Neurosurgery: 83

Drug cost

$2,951

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 52 $748
Cyclobenzaprine Hcl Generic 25 $576
Pregabalin Generic 13 $415
Tizanidine Hcl Generic 42 $376
Gabapentin Generic 31 $351
Meloxicam Generic 26 $217
Oxycodone Hcl Generic 32 $210
Ibuprofen Generic 11 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$160,080

Medicare's payments for the services billed

Medicare patients

272

Average age 73

Services billed

604

148 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 36%
Depression 36%
Chronic kidney disease 31%
Cancer 23%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record